PMID- 27706215
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20190212
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 10
DP  - 2016
TI  - Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional
      Neuroimaging Study.
PG  - e0163774
LID - 10.1371/journal.pone.0163774 [doi]
AB  - Alterations to myelin may be a core pathological feature of neurodegenerative
      diseases. Although white matter microstructural differences have been described
      in Parkinson's disease (PD), it is unknown whether such differences include
      alterations of the brain's myelin content. Thus, the objective of the current
      study is to measure and compare brain myelin content between PD patients and
      age-matched controls. In this cross-sectional study, 63 participants from the
      Longitudinal MRI in Parkinson's Disease study underwent brain MRI, Unified
      Parkinson's Disease Rating Scale (UPDRS) scoring, and cognitive asessments.
      Subjects were imaged with the mcDEPSOT (multi-component driven equilibrium single
      pulse observation of T1 and T2), a multicomponent relaxometry technique that
      quantifies longitudinal and transverse relaxation rates (R1 and R2, respectively)
      and the myelin water fraction (VFM), a surrogate for myelin content. A voxel-wise
      approach was used to compare R1, R2, and VFM measures between PD and control
      groups, and to evaluate relationships with age as well as disease duration, UPDRS
      scores, and daily levodopa equivalent dose. PD subjects had higher VFM than
      controls in frontal and temporal white matter and bilateral thalamus. Greater age
      was strongly associated with lower VFM in both groups, while an age-by-group
      interaction suggested a slower rate of VFM decline in the left putamen with aging
      in PD. Within the PD group, measures of disease severity, including UPDRS, daily 
      levodopa equivalent dose, and disease duration, were observed to be related with 
      myelin content in diffuse brain regions. The age-by-group interaction suggests
      that either PD or dopaminergic therapies allay observed age-related myelin
      changes. The relationships between VFM and disease severity measures suggests
      that VFM may provide a surrogate marker for microstructural changes related to
      Parkinson's disease.
FAU - Dean, Douglas C 3rd
AU  - Dean DC 3rd
AUID- ORCID: http://orcid.org/0000-0002-7057-1285
AD  - Waisman Center, University of Wisconsin Madison, Madison, Wisconsin, United
      States of America.
FAU - Sojkova, Jitka
AU  - Sojkova J
AD  - William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United
      States of America.
AD  - Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin,
      United States of America.
FAU - Hurley, Samuel
AU  - Hurley S
AD  - Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, University 
      of Oxford, Oxford, Oxfordshire, United Kingdom.
FAU - Kecskemeti, Steven
AU  - Kecskemeti S
AD  - Waisman Center, University of Wisconsin Madison, Madison, Wisconsin, United
      States of America.
FAU - Okonkwo, Ozioma
AU  - Okonkwo O
AD  - Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of 
      Medicine and Public Health, Madison, Wisconsin, United States of America.
FAU - Bendlin, Barbara B
AU  - Bendlin BB
AD  - Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of 
      Medicine and Public Health, Madison, Wisconsin, United States of America.
FAU - Theisen, Frances
AU  - Theisen F
AD  - William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United
      States of America.
AD  - Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin,
      United States of America.
FAU - Johnson, Sterling C
AU  - Johnson SC
AD  - William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United
      States of America.
AD  - Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of 
      Medicine and Public Health, Madison, Wisconsin, United States of America.
FAU - Alexander, Andrew L
AU  - Alexander AL
AD  - Waisman Center, University of Wisconsin Madison, Madison, Wisconsin, United
      States of America.
AD  - Department of Medical Physics, University of Wisconsin School of Medicine and
      Public Health, Madison, Wisconsin, United States of America.
AD  - Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisconsin,
      United States of America.
FAU - Gallagher, Catherine L
AU  - Gallagher CL
AD  - William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United
      States of America.
AD  - Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin,
      United States of America.
AD  - Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of 
      Medicine and Public Health, Madison, Wisconsin, United States of America.
LA  - eng
GR  - R01 AG037639/AG/NIA NIH HHS/United States
GR  - P30 HD003352/HD/NICHD NIH HHS/United States
GR  - I01 CX000555/CX/CSRD VA/United States
GR  - R01 AG027161/AG/NIA NIH HHS/United States
GR  - T32 HD007489/HD/NICHD NIH HHS/United States
GR  - R21 HD078119/HD/NICHD NIH HHS/United States
GR  - P50 AG033514/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20161005
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antiparkinson Agents)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Antiparkinson Agents/therapeutic use
MH  - Brain/diagnostic imaging
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Levodopa/therapeutic use
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Myelin Sheath/*pathology
MH  - Neuroimaging/*methods
MH  - Parkinson Disease/*diagnostic imaging/drug therapy
PMC - PMC5051727
COIS- The authors have declared that no competing interests exist.
EDAT- 2016/10/06 06:00
MHDA- 2017/06/18 06:00
CRDT- 2016/10/06 06:00
PHST- 2016/05/19 00:00 [received]
PHST- 2016/09/14 00:00 [accepted]
PHST- 2016/10/06 06:00 [entrez]
PHST- 2016/10/06 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
AID - 10.1371/journal.pone.0163774 [doi]
AID - PONE-D-16-20315 [pii]
PST - epublish
SO  - PLoS One. 2016 Oct 5;11(10):e0163774. doi: 10.1371/journal.pone.0163774.
      eCollection 2016.